Share Price and Basic Stock Data
Last Updated: December 4, 2025, 2:05 am
| PEG Ratio | 3.20 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Abbott India Ltd, operating in the pharmaceuticals sector, reported a share price of ₹29,770 and a market capitalization of ₹63,238 Cr. The company has shown a consistent upward trend in revenue, with sales rising from ₹4,093 Cr in FY 2020 to ₹5,349 Cr in FY 2023, and projected to reach ₹6,409 Cr in FY 2025. The trailing twelve months (TTM) revenue stood at ₹6,590 Cr, reflecting a robust demand for its products. Quarterly sales figures indicate a steady increase, with Q2 FY 2025 sales reaching ₹1,738 Cr, compared to ₹1,304 Cr in Q2 FY 2022. This growth trajectory is supported by a diverse product portfolio and strong market presence. Operating profit margins (OPM) have also improved, standing at 26% for FY 2025, up from 23% in FY 2023. The company’s ability to maintain a consistent revenue growth pattern underscores its competitive positioning in the pharmaceutical industry, which has seen varied performance across different companies.
Profitability and Efficiency Metrics
Abbott India Ltd reported a net profit of ₹1,452 Cr for the latest fiscal year, showcasing a significant increase from ₹949 Cr in FY 2023. The net profit margin stood at 22.06% for FY 2025, higher than the industry average, indicating effective cost management and operational efficiency. The company recorded a return on equity (ROE) of 35.7% and a return on capital employed (ROCE) of 46.2%, both of which are substantially above typical sector ranges. The interest coverage ratio (ICR) of 172.37x highlights the company’s strong ability to service its debt, providing a cushion against financial risk. Additionally, the cash conversion cycle (CCC) was reported at just 3 days, reflecting Abbott’s efficiency in managing working capital. This set of profitability and efficiency metrics positions Abbott India favorably against its peers, reinforcing its strong operational framework.
Balance Sheet Strength and Financial Ratios
Abbott India Ltd’s balance sheet remains robust, with total assets amounting to ₹5,917 Cr and reserves of ₹4,212 Cr. The company has maintained a conservative borrowing strategy, with total borrowings at ₹197 Cr, contributing to a healthy debt-to-equity ratio. The current ratio stands at 3.39, indicating excellent liquidity and the ability to cover short-term liabilities. Moreover, the price-to-book value (P/BV) ratio of 15.43x suggests that the stock is trading at a premium, reflecting investor confidence in its growth prospects. The company’s depreciation expenses have remained stable, facilitating consistent profit generation. With a solid foundation and low leverage, Abbott India is well-positioned to navigate potential economic fluctuations while pursuing growth opportunities in the pharmaceutical sector.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Abbott India Ltd reveals strong promoter confidence, with promoters holding 74.99% of the shares. This level of insider ownership indicates a commitment to the company’s long-term success. Foreign institutional investors (FIIs) hold a mere 0.16%, while domestic institutional investors (DIIs) account for 9.11%, reflecting limited foreign interest but a stable domestic investment base. The total number of shareholders stands at 71,199, suggesting a broad retail investor base. However, the relatively low foreign investment could indicate potential concerns about market dynamics or regulatory hurdles. Despite this, the continuous increase in domestic institutional ownership and the steady performance of the stock have likely bolstered investor confidence, aligning with the company’s growth trajectory.
Outlook, Risks, and Final Insight
Looking ahead, Abbott India Ltd is poised for continued growth, driven by its strong product pipeline and operational efficiencies. However, the company faces risks such as potential regulatory changes and competition within the pharmaceutical sector, which could impact market share and profitability. Additionally, fluctuations in raw material costs may affect margins. Nevertheless, the company’s solid financial metrics, including a high ROE and low debt levels, provide a cushion against these risks. In a scenario where the company successfully navigates these challenges, it could enhance its market positioning and profitability. Conversely, if external pressures mount, Abbott may need to implement strategic adjustments to sustain its growth momentum. Overall, Abbott India Ltd’s current strengths and proactive management strategies suggest a favorable outlook in the competitive pharmaceutical landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Abbott India Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 138 Cr. | 109 | 247/84.3 | 30.5 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,347 Cr. | 399 | 479/192 | 90.0 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.1 Cr. | 44.6 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 43.8 Cr. | 29.9 | 30.5/17.0 | 104 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,566.25 Cr | 1,174.15 | 52.64 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,304 | 1,379 | 1,322 | 1,343 | 1,479 | 1,494 | 1,437 | 1,439 | 1,558 | 1,633 | 1,614 | 1,605 | 1,738 |
| Expenses | 1,034 | 1,036 | 1,010 | 1,063 | 1,124 | 1,113 | 1,049 | 1,109 | 1,167 | 1,194 | 1,178 | 1,176 | 1,293 |
| Operating Profit | 270 | 343 | 312 | 280 | 355 | 381 | 388 | 330 | 391 | 439 | 436 | 429 | 446 |
| OPM % | 21% | 25% | 24% | 21% | 24% | 25% | 27% | 23% | 25% | 27% | 27% | 27% | 26% |
| Other Income | 27 | 34 | 44 | 50 | 56 | 56 | 56 | 81 | 67 | 60 | 72 | 76 | 73 |
| Interest | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 4 | 6 |
| Depreciation | 17 | 17 | 18 | 17 | 17 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 19 |
| Profit before tax | 275 | 355 | 335 | 308 | 390 | 415 | 422 | 390 | 437 | 479 | 488 | 483 | 493 |
| Tax % | 25% | 25% | 26% | 25% | 26% | 25% | 26% | 26% | 25% | 25% | 26% | 24% | 26% |
| Net Profit | 206 | 266 | 247 | 231 | 290 | 313 | 311 | 287 | 328 | 359 | 361 | 367 | 366 |
| EPS in Rs | 96.77 | 124.95 | 116.16 | 108.91 | 136.59 | 147.27 | 146.35 | 135.09 | 154.36 | 168.76 | 169.78 | 172.73 | 172.18 |
Last Updated: August 20, 2025, 12:45 am
Below is a detailed analysis of the quarterly data for Abbott India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1,738.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,605.00 Cr. (Mar 2025) to 1,738.00 Cr., marking an increase of 133.00 Cr..
- For Expenses, as of Jun 2025, the value is 1,293.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,176.00 Cr. (Mar 2025) to 1,293.00 Cr., marking an increase of 117.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 446.00 Cr.. The value appears strong and on an upward trend. It has increased from 429.00 Cr. (Mar 2025) to 446.00 Cr., marking an increase of 17.00 Cr..
- For OPM %, as of Jun 2025, the value is 26.00%. The value appears to be declining and may need further review. It has decreased from 27.00% (Mar 2025) to 26.00%, marking a decrease of 1.00%.
- For Other Income, as of Jun 2025, the value is 73.00 Cr.. The value appears to be declining and may need further review. It has decreased from 76.00 Cr. (Mar 2025) to 73.00 Cr., marking a decrease of 3.00 Cr..
- For Interest, as of Jun 2025, the value is 6.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.00 Cr. (Mar 2025) to 6.00 Cr., marking an increase of 2.00 Cr..
- For Depreciation, as of Jun 2025, the value is 19.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 18.00 Cr. (Mar 2025) to 19.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 493.00 Cr.. The value appears strong and on an upward trend. It has increased from 483.00 Cr. (Mar 2025) to 493.00 Cr., marking an increase of 10.00 Cr..
- For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 24.00% (Mar 2025) to 26.00%, marking an increase of 2.00%.
- For Net Profit, as of Jun 2025, the value is 366.00 Cr.. The value appears to be declining and may need further review. It has decreased from 367.00 Cr. (Mar 2025) to 366.00 Cr., marking a decrease of 1.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 172.18. The value appears to be declining and may need further review. It has decreased from 172.73 (Mar 2025) to 172.18, marking a decrease of 0.55.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:05 am
| Metric | Mar 2014n n 15m | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,276 | 2,289 | 2,614 | 2,903 | 3,298 | 3,679 | 4,093 | 4,310 | 4,913 | 5,349 | 5,849 | 6,409 | 6,590 |
| Expenses | 2,009 | 1,977 | 2,250 | 2,505 | 2,774 | 3,074 | 3,336 | 3,388 | 3,832 | 4,143 | 4,396 | 4,714 | 4,841 |
| Operating Profit | 267 | 312 | 365 | 398 | 525 | 605 | 757 | 922 | 1,082 | 1,206 | 1,453 | 1,695 | 1,749 |
| OPM % | 12% | 14% | 14% | 14% | 16% | 16% | 18% | 21% | 22% | 23% | 25% | 26% | 27% |
| Other Income | 49 | 48 | 50 | 57 | 117 | 113 | 114 | 81 | 83 | 154 | 248 | 275 | 281 |
| Interest | 0 | 0 | 3 | 2 | 4 | 2 | 9 | 18 | 19 | 16 | 12 | 11 | 14 |
| Depreciation | 22 | 15 | 14 | 16 | 16 | 17 | 60 | 58 | 66 | 70 | 71 | 72 | 73 |
| Profit before tax | 295 | 344 | 398 | 436 | 621 | 699 | 803 | 926 | 1,080 | 1,274 | 1,618 | 1,887 | 1,943 |
| Tax % | 33% | 34% | 36% | 37% | 35% | 36% | 26% | 25% | 26% | 25% | 26% | 25% | |
| Net Profit | 198 | 229 | 255 | 277 | 401 | 450 | 593 | 691 | 799 | 949 | 1,201 | 1,414 | 1,452 |
| EPS in Rs | 93.39 | 107.75 | 120.12 | 130.19 | 188.82 | 211.93 | 279.04 | 325.04 | 375.87 | 446.80 | 565.30 | 665.64 | 683.45 |
| Dividend Payout % | 25% | 29% | 29% | 31% | 29% | 31% | 90% | 85% | 73% | 73% | 73% | 71% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 11.35% | 8.63% | 44.77% | 12.22% | 31.78% | 16.53% | 15.63% | 18.77% | 26.55% | 17.74% |
| Change in YoY Net Profit Growth (%) | 0.00% | -2.73% | 36.14% | -32.55% | 19.56% | -15.25% | -0.90% | 3.14% | 7.78% | -8.82% |
Abbott India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 9% |
| 3 Years: | 9% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 19% |
| 3 Years: | 21% |
| TTM: | 17% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 14% |
| 3 Years: | 21% |
| 1 Year: | 8% |
| Return on Equity | |
|---|---|
| 10 Years: | 30% |
| 5 Years: | 32% |
| 3 Years: | 34% |
| Last Year: | 36% |
Last Updated: September 5, 2025, 2:01 pm
Balance Sheet
Last Updated: December 4, 2025, 2:16 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
| Reserves | 767 | 916 | 1,174 | 1,366 | 1,672 | 1,987 | 2,410 | 2,581 | 2,799 | 3,167 | 3,678 | 4,212 | 3,990 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 175 | 153 | 152 | 113 | 83 | 197 | 182 |
| Other Liabilities | 351 | 436 | 421 | 679 | 723 | 932 | 940 | 1,086 | 1,253 | 1,254 | 1,411 | 1,487 | 1,501 |
| Total Liabilities | 1,139 | 1,374 | 1,616 | 2,066 | 2,416 | 2,941 | 3,547 | 3,840 | 4,224 | 4,556 | 5,193 | 5,917 | 5,694 |
| Fixed Assets | 98 | 96 | 108 | 110 | 81 | 105 | 270 | 251 | 271 | 237 | 225 | 336 | 314 |
| CWIP | 1 | 4 | 3 | 6 | 2 | 1 | 2 | 1 | 1 | 4 | 10 | 18 | 23 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1,040 | 1,274 | 1,505 | 1,950 | 2,333 | 2,835 | 3,275 | 3,589 | 3,952 | 4,315 | 4,958 | 5,563 | 5,357 |
| Total Assets | 1,139 | 1,374 | 1,616 | 2,066 | 2,416 | 2,941 | 3,547 | 3,840 | 4,224 | 4,556 | 5,193 | 5,917 | 5,694 |
Below is a detailed analysis of the balance sheet data for Abbott India Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 21.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 21.00 Cr..
- For Reserves, as of Sep 2025, the value is 3,990.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4,212.00 Cr. (Mar 2025) to 3,990.00 Cr., marking a decrease of 222.00 Cr..
- For Borrowings, as of Sep 2025, the value is 182.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 197.00 Cr. (Mar 2025) to 182.00 Cr., marking a decrease of 15.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,501.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,487.00 Cr. (Mar 2025) to 1,501.00 Cr., marking an increase of 14.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 5,694.00 Cr.. The value appears to be improving (decreasing). It has decreased from 5,917.00 Cr. (Mar 2025) to 5,694.00 Cr., marking a decrease of 223.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 314.00 Cr.. The value appears to be declining and may need further review. It has decreased from 336.00 Cr. (Mar 2025) to 314.00 Cr., marking a decrease of 22.00 Cr..
- For CWIP, as of Sep 2025, the value is 23.00 Cr.. The value appears strong and on an upward trend. It has increased from 18.00 Cr. (Mar 2025) to 23.00 Cr., marking an increase of 5.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 5,357.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5,563.00 Cr. (Mar 2025) to 5,357.00 Cr., marking a decrease of 206.00 Cr..
- For Total Assets, as of Sep 2025, the value is 5,694.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5,917.00 Cr. (Mar 2025) to 5,694.00 Cr., marking a decrease of 223.00 Cr..
Notably, the Reserves (3,990.00 Cr.) exceed the Borrowings (182.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014n n 15m | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 267.00 | 312.00 | 365.00 | 398.00 | 525.00 | 605.00 | 582.00 | 769.00 | -151.00 | -112.00 | -82.00 | -196.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 18 | 21 | 20 | 22 | 29 | 27 | 28 | 21 | 21 | 22 | 20 | 22 |
| Inventory Days | 101 | 107 | 91 | 107 | 112 | 106 | 83 | 110 | 94 | 80 | 70 | 92 |
| Days Payable | 38 | 54 | 56 | 101 | 92 | 116 | 104 | 116 | 122 | 109 | 114 | 110 |
| Cash Conversion Cycle | 80 | 74 | 54 | 28 | 49 | 17 | 8 | 14 | -6 | -8 | -24 | 3 |
| Working Capital Days | 36 | 30 | 32 | 21 | 63 | 22 | 10 | 7 | -7 | -8 | -14 | 97 |
| ROCE % | 39% | 40% | 38% | 34% | 41% | 37% | 35% | 35% | 38% | 41% | 46% | 46% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Large & Midcap Fund | 274,878 | 2.24 | 797.01 | 155,000 | 2025-10-30 02:04:49 | 77.34% |
| Axis Midcap Fund | 166,043 | 1.5 | 481.44 | 164,230 | 2025-10-30 04:11:08 | 1.1% |
| Canara Robeco Large and Mid Cap Fund | 144,836 | 1.6 | 419.95 | N/A | N/A | N/A |
| Nippon India Multi Cap Fund | 87,483 | 0.51 | 253.66 | 44,742 | 2025-10-30 04:11:08 | 95.53% |
| SBI MNC Fund | 80,000 | 3.89 | 231.96 | N/A | N/A | N/A |
| PGIM India Midcap Fund | 74,300 | 1.86 | 215.43 | N/A | N/A | N/A |
| Nippon India Pharma Fund | 68,677 | 2.39 | 199.13 | 76,390 | 2025-10-30 04:11:08 | -10.1% |
| Franklin India Mid Cap Fund | 52,304 | 1.19 | 151.66 | N/A | N/A | N/A |
| SBI Healthcare Opportunities Fund | 40,000 | 2.84 | 115.98 | N/A | N/A | N/A |
| Canara Robeco Flexi Cap Fund | 32,022 | 0.67 | 92.85 | 42,310 | 2025-10-30 04:11:08 | -24.32% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 665.62 | 565.28 | 446.78 | 375.86 | 325.04 |
| Diluted EPS (Rs.) | 665.62 | 565.28 | 446.78 | 375.86 | 325.04 |
| Cash EPS (Rs.) | 699.41 | 598.77 | 479.71 | 406.96 | 352.38 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 1992.07 | 1740.65 | 1500.49 | 1326.96 | 1224.55 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 1992.07 | 1740.65 | 1500.49 | 1326.96 | 1224.55 |
| Dividend / Share (Rs.) | 475.00 | 410.00 | 325.00 | 275.00 | 275.00 |
| Revenue From Operations / Share (Rs.) | 3016.07 | 2752.43 | 2517.05 | 2314.95 | 2028.24 |
| PBDIT / Share (Rs.) | 927.14 | 800.64 | 639.90 | 548.20 | 471.70 |
| PBIT / Share (Rs.) | 893.36 | 767.15 | 606.97 | 517.10 | 444.34 |
| PBT / Share (Rs.) | 887.98 | 761.29 | 599.44 | 508.11 | 435.74 |
| Net Profit / Share (Rs.) | 665.62 | 565.28 | 446.78 | 375.86 | 325.03 |
| PBDIT Margin (%) | 30.74 | 29.08 | 25.42 | 23.68 | 23.25 |
| PBIT Margin (%) | 29.61 | 27.87 | 24.11 | 22.33 | 21.90 |
| PBT Margin (%) | 29.44 | 27.65 | 23.81 | 21.94 | 21.48 |
| Net Profit Margin (%) | 22.06 | 20.53 | 17.75 | 16.23 | 16.02 |
| Return on Networth / Equity (%) | 33.41 | 32.47 | 29.77 | 28.32 | 26.54 |
| Return on Capital Employeed (%) | 42.09 | 42.33 | 38.50 | 36.37 | 33.60 |
| Return On Assets (%) | 23.90 | 23.12 | 20.84 | 18.90 | 17.98 |
| Asset Turnover Ratio (%) | 1.15 | 1.20 | 1.22 | 1.22 | 1.17 |
| Current Ratio (X) | 3.39 | 2.42 | 2.51 | 3.20 | 3.41 |
| Quick Ratio (X) | 2.76 | 1.96 | 1.97 | 2.63 | 2.72 |
| Inventory Turnover Ratio (X) | 8.54 | 9.22 | 0.83 | 0.70 | 0.72 |
| Dividend Payout Ratio (NP) (%) | 61.59 | 57.49 | 61.54 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 58.61 | 54.27 | 57.32 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 38.41 | 42.51 | 38.46 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 41.39 | 45.73 | 42.68 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 172.37 | 136.66 | 85.04 | 60.99 | 54.83 |
| Interest Coverage Ratio (Post Tax) (X) | 124.75 | 97.48 | 60.38 | 42.82 | 38.78 |
| Enterprise Value (Cr.) | 63674.71 | 55125.76 | 44996.86 | 34862.11 | 29441.84 |
| EV / Net Operating Revenue (X) | 9.93 | 9.42 | 8.41 | 7.09 | 6.83 |
| EV / EBITDA (X) | 32.32 | 32.40 | 33.09 | 29.93 | 29.37 |
| MarketCap / Net Operating Revenue (X) | 10.19 | 9.79 | 8.77 | 7.65 | 7.39 |
| Retention Ratios (%) | 38.40 | 42.50 | 38.45 | 0.00 | 0.00 |
| Price / BV (X) | 15.43 | 15.48 | 14.72 | 13.34 | 12.24 |
| Price / Net Operating Revenue (X) | 10.19 | 9.79 | 8.77 | 7.65 | 7.39 |
| EarningsYield | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
After reviewing the key financial ratios for Abbott India Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 665.62. This value is within the healthy range. It has increased from 565.28 (Mar 24) to 665.62, marking an increase of 100.34.
- For Diluted EPS (Rs.), as of Mar 25, the value is 665.62. This value is within the healthy range. It has increased from 565.28 (Mar 24) to 665.62, marking an increase of 100.34.
- For Cash EPS (Rs.), as of Mar 25, the value is 699.41. This value is within the healthy range. It has increased from 598.77 (Mar 24) to 699.41, marking an increase of 100.64.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1,992.07. It has increased from 1,740.65 (Mar 24) to 1,992.07, marking an increase of 251.42.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1,992.07. It has increased from 1,740.65 (Mar 24) to 1,992.07, marking an increase of 251.42.
- For Dividend / Share (Rs.), as of Mar 25, the value is 475.00. This value exceeds the healthy maximum of 3. It has increased from 410.00 (Mar 24) to 475.00, marking an increase of 65.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 3,016.07. It has increased from 2,752.43 (Mar 24) to 3,016.07, marking an increase of 263.64.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 927.14. This value is within the healthy range. It has increased from 800.64 (Mar 24) to 927.14, marking an increase of 126.50.
- For PBIT / Share (Rs.), as of Mar 25, the value is 893.36. This value is within the healthy range. It has increased from 767.15 (Mar 24) to 893.36, marking an increase of 126.21.
- For PBT / Share (Rs.), as of Mar 25, the value is 887.98. This value is within the healthy range. It has increased from 761.29 (Mar 24) to 887.98, marking an increase of 126.69.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 665.62. This value is within the healthy range. It has increased from 565.28 (Mar 24) to 665.62, marking an increase of 100.34.
- For PBDIT Margin (%), as of Mar 25, the value is 30.74. This value is within the healthy range. It has increased from 29.08 (Mar 24) to 30.74, marking an increase of 1.66.
- For PBIT Margin (%), as of Mar 25, the value is 29.61. This value exceeds the healthy maximum of 20. It has increased from 27.87 (Mar 24) to 29.61, marking an increase of 1.74.
- For PBT Margin (%), as of Mar 25, the value is 29.44. This value is within the healthy range. It has increased from 27.65 (Mar 24) to 29.44, marking an increase of 1.79.
- For Net Profit Margin (%), as of Mar 25, the value is 22.06. This value exceeds the healthy maximum of 10. It has increased from 20.53 (Mar 24) to 22.06, marking an increase of 1.53.
- For Return on Networth / Equity (%), as of Mar 25, the value is 33.41. This value is within the healthy range. It has increased from 32.47 (Mar 24) to 33.41, marking an increase of 0.94.
- For Return on Capital Employeed (%), as of Mar 25, the value is 42.09. This value is within the healthy range. It has decreased from 42.33 (Mar 24) to 42.09, marking a decrease of 0.24.
- For Return On Assets (%), as of Mar 25, the value is 23.90. This value is within the healthy range. It has increased from 23.12 (Mar 24) to 23.90, marking an increase of 0.78.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.15. It has decreased from 1.20 (Mar 24) to 1.15, marking a decrease of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 3.39. This value exceeds the healthy maximum of 3. It has increased from 2.42 (Mar 24) to 3.39, marking an increase of 0.97.
- For Quick Ratio (X), as of Mar 25, the value is 2.76. This value exceeds the healthy maximum of 2. It has increased from 1.96 (Mar 24) to 2.76, marking an increase of 0.80.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 8.54. This value exceeds the healthy maximum of 8. It has decreased from 9.22 (Mar 24) to 8.54, marking a decrease of 0.68.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 61.59. This value exceeds the healthy maximum of 50. It has increased from 57.49 (Mar 24) to 61.59, marking an increase of 4.10.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 58.61. This value exceeds the healthy maximum of 50. It has increased from 54.27 (Mar 24) to 58.61, marking an increase of 4.34.
- For Earning Retention Ratio (%), as of Mar 25, the value is 38.41. This value is below the healthy minimum of 40. It has decreased from 42.51 (Mar 24) to 38.41, marking a decrease of 4.10.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 41.39. This value is within the healthy range. It has decreased from 45.73 (Mar 24) to 41.39, marking a decrease of 4.34.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 172.37. This value is within the healthy range. It has increased from 136.66 (Mar 24) to 172.37, marking an increase of 35.71.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 124.75. This value is within the healthy range. It has increased from 97.48 (Mar 24) to 124.75, marking an increase of 27.27.
- For Enterprise Value (Cr.), as of Mar 25, the value is 63,674.71. It has increased from 55,125.76 (Mar 24) to 63,674.71, marking an increase of 8,548.95.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 9.93. This value exceeds the healthy maximum of 3. It has increased from 9.42 (Mar 24) to 9.93, marking an increase of 0.51.
- For EV / EBITDA (X), as of Mar 25, the value is 32.32. This value exceeds the healthy maximum of 15. It has decreased from 32.40 (Mar 24) to 32.32, marking a decrease of 0.08.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 10.19. This value exceeds the healthy maximum of 3. It has increased from 9.79 (Mar 24) to 10.19, marking an increase of 0.40.
- For Retention Ratios (%), as of Mar 25, the value is 38.40. This value is within the healthy range. It has decreased from 42.50 (Mar 24) to 38.40, marking a decrease of 4.10.
- For Price / BV (X), as of Mar 25, the value is 15.43. This value exceeds the healthy maximum of 3. It has decreased from 15.48 (Mar 24) to 15.43, marking a decrease of 0.05.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 10.19. This value exceeds the healthy maximum of 3. It has increased from 9.79 (Mar 24) to 10.19, marking an increase of 0.40.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Abbott India Ltd:
- Net Profit Margin: 22.06%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 42.09% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 33.41% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 124.75
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.76
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 40.7 (Industry average Stock P/E: 52.64)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 22.06%
About the Company
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 3, Corporate Park, Mumbai Maharashtra 400071 | investorrelations.india@abbott.com http://www.abbott.co.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Munir Shaikh | Chairman |
| Mr. Vivek V Kamath | Managing Director |
| Mr. Kaiyomarz Marfatia | Non Executive Director |
| Mr. Ambati Venu | Non Executive Director |
| Mr. Sabina Ewing | Non Executive Director |
| Ms. Anisha Motwani | Independent Director |
| Ms. Shalini Kamath | Independent Director |
| Mr. Sudarshan Jain | Independent Director |
| Mr. Mahadeo Karnik | Non Executive Director |
Abbott India Ltd. Share Price Update | |
|---|---|
| Share Price | Value |
| Today | ₹26,498.10 |
| Previous Day | ₹26,643.70 |
FAQ
What is the intrinsic value of Abbott India Ltd?
Abbott India Ltd's intrinsic value (as of 04 December 2025) is 22305.87 which is 22.79% lower the current market price of 28,890.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 61,403 Cr. market cap, FY2025-2026 high/low of 37,000/25,260, reserves of ₹3,990 Cr, and liabilities of 5,694 Cr.
What is the Market Cap of Abbott India Ltd?
The Market Cap of Abbott India Ltd is 61,403 Cr..
What is the current Stock Price of Abbott India Ltd as on 04 December 2025?
The current stock price of Abbott India Ltd as on 04 December 2025 is 28,890.
What is the High / Low of Abbott India Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Abbott India Ltd stocks is 37,000/25,260.
What is the Stock P/E of Abbott India Ltd?
The Stock P/E of Abbott India Ltd is 40.7.
What is the Book Value of Abbott India Ltd?
The Book Value of Abbott India Ltd is 1,888.
What is the Dividend Yield of Abbott India Ltd?
The Dividend Yield of Abbott India Ltd is 1.64 %.
What is the ROCE of Abbott India Ltd?
The ROCE of Abbott India Ltd is 46.2 %.
What is the ROE of Abbott India Ltd?
The ROE of Abbott India Ltd is 35.7 %.
What is the Face Value of Abbott India Ltd?
The Face Value of Abbott India Ltd is 10.0.